8 February 2016 - NICE has published draft guidance not recommending alirocumab (Praluent, Sanofi/Regeneron) as an option for people with high cholesterol (primary hypercholesterolaemia - heterozygous-familial and non-familial) and mixed dyslipidaemia.

For more details, go to: http://www.nice.org.uk/news/press-and-media/nice-issues-draft-guidance-on-alirocumab-for-lipid-disorder